Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.